Related Experiment Video
Updated: May 27, 2026
06:48
Limbal Approach-Subretinal Injection of Viral Vectors for Gene Therapy in Mice Retinal Pigment Epithelium
Published on: August 7, 2015
Gene transfer for ocular neovascularization and macular edema
1Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD 21287-9277, USA. pcampo@jhmi.edu
Gene Therapy
|November 11, 2011
Summary
Gene therapy offers a promising alternative to frequent eye injections for vision loss caused by abnormal blood vessel growth. This approach aims for long-term suppression of neovascularization and leakage, potentially improving patient outcomes.
Area of Science:
- Ophthalmology
- Molecular Biology
- Genetics
Background:
- Neovascularization and vascular leakage are leading causes of vision loss globally.
- Current treatments, like intraocular injections, offer benefits but can have suboptimal responses and require frequent administration.
- Understanding the molecular basis of these diseases has paved the way for novel therapeutic strategies.
Purpose of the Study:
- To explore gene transfer of antiangiogenic proteins as a potential long-term treatment for ocular neovascularization and leakage.
- To evaluate the efficacy of gene therapy in preclinical models and early-phase clinical trials for vision-threatening eye diseases.
Main Methods:
- Utilizing gene transfer techniques with viral vectors (e.g., adeno-associated virus, lentivirus) to deliver therapeutic genes into ocular tissues.
- Testing the efficacy of transgenes encoding antiangiogenic factors in animal models of ocular neovascularization.
- Conducting clinical trials to assess the safety and proof-of-concept for gene therapy in patients with conditions like neovascular age-related macular degeneration.
Main Results:
- Preclinical studies in animal models demonstrated significant suppression of ocular neovascularization using various transgenes.
- A clinical trial in patients with advanced neovascular age-related macular degeneration provided proof-of-concept for gene therapy's potential.
- Ongoing trials with AAV and lentiviral vectors expressing specific antiangiogenic proteins are expected to yield further valuable data.
Conclusions:
- Gene transfer of antiangiogenic proteins presents a viable alternative to conventional treatments for managing ocular neovascularization and leakage.
- This approach holds the potential for sustained therapeutic effects, addressing limitations of current therapies.
- Further clinical investigations are crucial to establish gene therapy as a standard treatment for vision-threatening eye conditions.
